Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries.

Hdl Handle:
http://hdl.handle.net/10144/18253
Title:
Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries.
Authors:
Zachariah, Rony; Harries, A D; Luo, Chewe; Bachman, Gretchen; Graham, S M
Journal:
The Lancet Infectious Diseases
Abstract:
Co-trimoxazole (trimethoprim-sulfamethoxazole) is a widely available antibiotic that substantially reduces HIV-related morbidity and mortality in both adults and children. Prophylaxis with co-trimoxazole is a recommended intervention of proven benefit that could serve not only as an initial step towards improving paediatric care in young children with limited access to antiretroviral treatment, but also as an important complement to antiretroviral therapy in resource-limited settings. Despite co-trimoxazole's known clinical benefits, the potential operational benefits, and favourable recommendations by WHO, UNAIDS, and UNICEF, its routine use in developing countries--particularly sub-Saharan Africa--has remained limited. Out of an estimated 4 million children in need of co-trimoxazole prophylaxis (HIV-exposed and HIV-infected), only 4% are currently receiving this intervention. We discuss some of the major barriers preventing the scale-up of co-trimoxazole prophylaxis for children in countries with a high prevalence of HIV and propose specific actions required to tackle these challenges.
Affiliation:
Médecins Sans Frontières, Medical department (Operational Research), Brussels Operational Center, Brussels, Belgium. zachariah@internet.lu
Publisher:
Elsevier
Issue Date:
Oct-2007
URI:
http://hdl.handle.net/10144/18253
DOI:
10.1016/S1473-3099(07)70239-6
PubMed ID:
17897611
Additional Links:
http://www.thelancet.com/journals/laninf
Language:
en
ISSN:
1473-3099
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorZachariah, Rony-
dc.contributor.authorHarries, A D-
dc.contributor.authorLuo, Chewe-
dc.contributor.authorBachman, Gretchen-
dc.contributor.authorGraham, S M-
dc.date.accessioned2008-02-14T10:54:19Z-
dc.date.available2008-02-14T10:54:19Z-
dc.date.issued2007-10-
dc.identifier.citationScaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries. 2007, 7 (10):686-93notLancet Infect Disen
dc.identifier.issn1473-3099-
dc.identifier.pmid17897611-
dc.identifier.doi10.1016/S1473-3099(07)70239-6-
dc.identifier.urihttp://hdl.handle.net/10144/18253-
dc.description.abstractCo-trimoxazole (trimethoprim-sulfamethoxazole) is a widely available antibiotic that substantially reduces HIV-related morbidity and mortality in both adults and children. Prophylaxis with co-trimoxazole is a recommended intervention of proven benefit that could serve not only as an initial step towards improving paediatric care in young children with limited access to antiretroviral treatment, but also as an important complement to antiretroviral therapy in resource-limited settings. Despite co-trimoxazole's known clinical benefits, the potential operational benefits, and favourable recommendations by WHO, UNAIDS, and UNICEF, its routine use in developing countries--particularly sub-Saharan Africa--has remained limited. Out of an estimated 4 million children in need of co-trimoxazole prophylaxis (HIV-exposed and HIV-infected), only 4% are currently receiving this intervention. We discuss some of the major barriers preventing the scale-up of co-trimoxazole prophylaxis for children in countries with a high prevalence of HIV and propose specific actions required to tackle these challenges.en
dc.language.isoenen
dc.publisherElsevier-
dc.relation.urlhttp://www.thelancet.com/journals/laninf-
dc.rightsReproduced on this site with permission of Elsevier Ltd. Please see www.TheLancet.com/journals/laninf for further relevant comment.en
dc.subject.meshAIDS-Related Opportunistic Infectionsen
dc.subject.meshAdolescenten
dc.subject.meshAnti-Infective Agentsen
dc.subject.meshChemopreventionen
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshDeveloping Countriesen
dc.subject.meshHIV Infectionsen
dc.subject.meshHealth Policyen
dc.subject.meshHumansen
dc.subject.meshInfanten
dc.subject.meshInfant, Newbornen
dc.subject.meshPrevalenceen
dc.subject.meshTrimethoprim-Sulfamethoxazole Combinationen
dc.titleScaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries.en
dc.contributor.departmentMédecins Sans Frontières, Medical department (Operational Research), Brussels Operational Center, Brussels, Belgium. zachariah@internet.luen
dc.identifier.journalThe Lancet Infectious Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.